“…As shown in Figure 1, since its first use for optical mapping in 2007, blebbistatin has all but replaced the other available EC uncouplers. In fact, in the last three years alone, blebbistatin was used twice as often (1,29,36,41,51,56,59,69,74,76,78,83,85,87) as any other uncoupler for imaging applications (25,27,33,46,54,55,80). The use of BDM/DAM and CytoD for optical mapping has essentially ceased, yet due to its lower cost, BDM/DAM may still be a reasonable choice for larger animal (i.e., non-rodent) studies (10,23,25,35,52,70,77), which require larger amounts of an EC uncoupler (72).…”